Hemab Therapeutics (NASDAQ:COAG) Stock Price Down 5.7% – Should You Sell?

Shares of Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) fell 5.7% on Monday . The company traded as low as $38.84 and last traded at $38.85. Approximately 144,442 shares were traded during trading, a decline of 61% from the average session volume of 367,478 shares. The stock had previously closed at $41.19.

Analysts Set New Price Targets

COAG has been the subject of several research reports. Wedbush raised their price target on Hemab Therapeutics from $55.00 to $64.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. Weiss Ratings started coverage on shares of Hemab Therapeutics in a research report on Thursday, August 13th. They issued a “sell (d+)” rating on the stock. The Goldman Sachs Group assumed coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $36.00 price target on the stock. Evercore started coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 price objective for the company. Finally, Zacks Research raised Hemab Therapeutics to a “hold” rating in a report on Wednesday, May 27th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $51.40.

Hemab Therapeutics Stock Up 0.7%

The company’s 50-day moving average is $46.66. The firm has a market cap of $1.79 billion and a P/E ratio of -1.54.

Hemab Therapeutics (NASDAQ:COAG) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.17). As a group, equities research analysts expect that Hemab Therapeutics Holdings, Inc. will post -3.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Hemab Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Squarepoint Ops LLC bought a new stake in shares of Hemab Therapeutics during the 2nd quarter worth approximately $230,000. The Manufacturers Life Insurance Company acquired a new position in Hemab Therapeutics during the second quarter valued at approximately $688,000. Opaleye Management Inc. bought a new stake in Hemab Therapeutics during the second quarter worth $1,750,000. State Street Corp acquired a new stake in shares of Hemab Therapeutics in the 2nd quarter valued at $2,825,000. Finally, Braidwell LP bought a new position in shares of Hemab Therapeutics in the 2nd quarter valued at $5,877,000.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious and underserved bleeding disorders. The company aims to create therapies that address limitations of existing approaches, including the need for frequent administration and the challenges associated with complex blood-product-based treatments.

Its lead investigational program, HMB-001, is being developed for Glanzmann thrombasthenia, a rare inherited disorder in which platelets do not function properly and can cause severe bleeding.